Trial reportBlood advances2019
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.
Trial report in Blood advances, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06.Haematologica · 2021Trial
- Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial.Blood advances · 2020Trial
- Genomic structural variations contribute to inform prognosis in patients with cytogenetically normal acute myeloid leukemia.Blood cancer journal · 2026Article
- Rare Genetic and Uncommon Morphological Entities in Adults with Acute Myeloid Leukemia.Current oncology reports · 2025Review
- Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions.International journal of molecular sciences · 2025Review
- Single cell RNA sequencing improves the next generation of approaches to AML treatment: challenges and perspectives.Molecular medicine (Cambridge, Mass.) · 2025Review
- Current status and research directions in acute myeloid leukemia.Blood cancer journal · 2024Review
- Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia.Haematologica · 2024Article
- The Therapeutic Potential of a Strategy to Prevent Acute Myeloid Leukemia Stem Cell Reprogramming in Older Patients.International journal of molecular sciences · 2023Review
- A Question of Frame: The Role of the Bone Marrow Stromal Niche in Myeloid Malignancies.HemaSphere · 2023Review
- Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia.Nature communications · 2023Article
- Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia.Frontiers in oncology · 2023Article
- Prognostic Relevance ofCancers · 2022Article
- Prediction of life-threatening and disabling bleeding in patients with AML receiving intensive induction chemotherapy.Blood advances · 2022Article
- Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study.Annals of hematology · 2022Observational
- Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades.Clinical lymphoma, myeloma & leukemia · 2021Review
- Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.Cancer · 2021Review
- Acute myeloid leukemia: current progress and future directions.Blood cancer journal · 2021Review
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 15 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Here we evaluated whether sequential high-dose chemotherapy (sHD) increased the early complete remission (CR) rate in acute myelogenous leukemia (AML) compared with standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy. This study enrolled 574 patients (age, 16-73 years; median, 52 years) who were randomly assigned to ICE (n = 286 evaluable) or sHD (2 weekly 3-day blocks with cytarabine 2 g/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.